Product details

By continuing to use our site you consent to the use of cookies as described in our privacy policy unless you have disabled them.
You can change your cookie settings at any time but parts of our site will not function correctly without them.
Published by: Global Health Delivery Project (GHD)
Originally published in: 2019
Version: September 2018
Revision date: 15-Aug-2019
Notes: This item is part of a free case collection. For terms & conditions go to www.thecasecentre.org/freecaseterms

Abstract

This case describes the development and rollout of bivalent oral polio vaccine (bOPV), starting in 2007, to support the Global Polio Eradication Initiative (GPEI) in eliminating poliovirus. After providing background on the global polio eradication program, the case explores the policy decisions behind the development of bOPV, progression through clinical trials, licensure, and distribution of the vaccine. In particular, the case examines the role of the World Health Organization (WHO) in accelerating the progression through these stages. The case study ends with Steve Cochi and Roland Sutter of WHO reflecting on the successes of bOPV and its impact on the eradication program at a global level. This case is part of the Global Health Delivery Project free case collection (visit www.thecasecentre.org/ghdfreecases for more information on the collection).

Teaching and learning

This item is suitable for executive education courses.

Time period

The events covered by this case took place in 2007-2018.

Geographical setting

Region:
Asia
Country:
India

Featured company

World Health Organization
Employees:
5001-10000
Type:
Government agency
Industry:
Global health
Other keywords:
Multilateral agency; Public health

Featured protagonists

  • Roland Sutter (male), Coordinator of the Research and Product Development Team of the Global Polio Eradication Initiative at the World Health Organization
  • Steve Cochi (male), Chair of the Advisory Committee on Polio Eradication
  • Bruce Aylward (male)

About

Abstract

This case describes the development and rollout of bivalent oral polio vaccine (bOPV), starting in 2007, to support the Global Polio Eradication Initiative (GPEI) in eliminating poliovirus. After providing background on the global polio eradication program, the case explores the policy decisions behind the development of bOPV, progression through clinical trials, licensure, and distribution of the vaccine. In particular, the case examines the role of the World Health Organization (WHO) in accelerating the progression through these stages. The case study ends with Steve Cochi and Roland Sutter of WHO reflecting on the successes of bOPV and its impact on the eradication program at a global level. This case is part of the Global Health Delivery Project free case collection (visit www.thecasecentre.org/ghdfreecases for more information on the collection).

Teaching and learning

This item is suitable for executive education courses.

Settings

Time period

The events covered by this case took place in 2007-2018.

Geographical setting

Region:
Asia
Country:
India

Featured company

World Health Organization
Employees:
5001-10000
Type:
Government agency
Industry:
Global health
Other keywords:
Multilateral agency; Public health

Featured protagonists

  • Roland Sutter (male), Coordinator of the Research and Product Development Team of the Global Polio Eradication Initiative at the World Health Organization
  • Steve Cochi (male), Chair of the Advisory Committee on Polio Eradication
  • Bruce Aylward (male)

Related